Drug Sheds 28% of Weight; Universal T1D Screening? Lilly Accuses Church of Fraud

Patients with obesity dropped a mean 28% of their body weight with a 12-mg dose of the investigational triple-receptor agonist retatrutide over 80 weeks in a phase III study, Eli Lilly announced. Nearly half had weight loss of 30% or greater, levels typically only seen with bariatric surgery.

There was little to no benefit from using calcium and/or vitamin D supplements to prevent fractures and falls, a systematic review and meta-analysis of 69 randomized trials found. (The BMJ)

Rates of early-stage type 1 diabetes (T1D) and progression to clinical diabetes were similar regardless of family history in a screening study of children in Germany, suggesting that screening could be considered beyond genetically at-risk populations. (JAMA)

Patients with anorexia, bulimia, and other eating disorders are taking GLP-1 medications, alarming doctors. (Washington Post)

Maryland’s Prescription Drug Affordability Board voted to put an upper payment limit on semaglutide (Ozempic) for type 2 diabetes, which would save the state an estimated $5.8 million per year. (Maryland Matters)

Prevalence of type 2 diabetes among adolescents ages 10 to 17 was nearly fourfold higher in 2022-2024 compared with a 2017 estimate of youth ages 10 to 19. (JAMA Pediatrics)

Young patients with Prader-Willi syndrome initially achieved clinically relevant weight loss with laparoscopic sleeve gastrectomy, but long-term benefits were markedly attenuated versus non-syndromic peers. (Journal of Clinical Endocrinology & Metabolism)

Nearly half (47%) of American Association of Clinical Endocrinology members said in a survey that they would use thyroid hormones in female euthyroid patients with infertility and elevated thyroid antibodies. (AACE Endocrinology & Diabetes)

Meanwhile, levothyroxine plus adjunct liothyronine treatment was associated with an increased risk for any psychiatric morbidity in patients with autoimmune hypothyroidism, a Swedish cohort study found. (Journal of the Endocrine Society)

The Trump administration’s crackdown on gender-affirming care has affected adults as well as children. (NBC News)

A pilot, primary care-based weight management program at UNC Health aimed at eliminating barriers to obesity care has successfully scaled and expanded across North Carolina since its launch in 2019. (NEJM Catalyst)

Pervasive misinformation about perimenopause on social media could put women at risk, The Guardian warned.

Eli Lilly accused several bishops at a Pentecostal church of a fraud scheme involving $200 million in illegitimate rebates submitted for dulaglutide (Trulicity). (CNBC)

Low-insulinemic and planetary health diets were linked with less weight gain during menopause in a prospective cohort study. (JAMA Network Open)